T Cell Non-Hodgkin Lymphoma

Its recognition is crucial, as ALK-positive ALCL generally responds well to therapy. Further studies are required to better define the clinical and prognostic implications of this presentation.

P2, N=155, Active, not recruiting, Daiichi Sankyo | Trial completion date: Sep 2025 --> Feb 2027

The proliferation, gemcitabine sensitivity and apoptosis of NKTCL cells were assessed by CCK-8 assays and flow cytometry...In summary, RHOA is a critical downstream effector of GNAQ in NKTCL. GNAQ promotes RHOA activation through ARHGEF25, which in turn regulates cellular functions by modulating cell proliferation and apoptosis, thereby influencing the progression of NKTCL.

P1, N=43, Active, not recruiting, UNC Lineberger Comprehensive Cancer Center | Recruiting --> Active, not recruiting | Trial completion date: Sep 2041 --> Nov 2039 | Trial primary completion date: Sep 2026 --> Dec 2025

The index case report highlights the diagnostic complexities of the small cell variant of ALCL and emphasises the utility of various ancillary techniques like immunophenotyping and FISH, in conjunction with cytomorphology, in confirming such a challenging diagnosis.

P=N/A, N=3000, Recruiting, Fudan University

A carefully staged treatment plan was employed, beginning with corticosteroids and etoposide, followed by liposomal mitoxantrone and the CD30-targeted antibody-drug conjugate brentuximab vedotin. The clinical course highlights the necessity of maintaining a high index of suspicion for lymphoma in refractory joint infections and demonstrates that individualized, stepwise therapy can achieve remission even in critically ill patients with aggressive ALCL. These findings provide valuable insights for improving the diagnosis and management of lymphoma cases that mimic infectious diseases.

In patients with chronic diarrhea and refractory skin ulcers, celiac disease should be excluded, while cutaneous lesions should be recognized as potential paraneoplastic manifestations of an underlying lymphoma. Diagnostic delays-driven by anchoring bias and insufficient tissue sampling-are critical contributors to advanced disease at presentation and poor clinical outcomes.

This case adds to the spectrum of SPTCL presentations, emphasizing the importance of considering SPTCL in panniculitis-like lesions refractory to conventional treatment. Prompt histopathological evaluation with immunophenotyping is crucial for early diagnosis and appropriate management to improve patient outcomes.

The clinical course was aggressive, and the patient died of the disease on the 13th day of hospitalization. This case highlights the potential for aggressive T-cell lymphoma to emerge during bispecific antibody therapy, a phenomenon that has also been noted in the context of CAR-T cell therapy.

These findings suggest the follicular microenvironment may provide survival advantages to malignant T cells while promoting a dysregulated anti-tumor immune response. These observations provide insight into the mechanisms underlying the more aggressive clinical features of FMF versus CMF.

Patient education and a multidisciplinary team approach allow for timely diagnosis and complete surgical excision, which are key for a good prognosis. Clinical and radiological surveillance detect early recurrence and assess need for adjuvant therapy.